But Im not sure that the figures you mentioned say something different than the article.
It says: "However, sales of Relenza RECENTLY outpaced Tamiflu..."
Probably the guys from iStockAnalyst have some inside- infos about sales of the 3rd quarter that has ended today, and thats what they meant by "recently". If not it would be a bit strange, since the figures you mentioned for the 2nd quarter make very clear that Tamiflu sold more than Relenza.
I totally agree with you that GSK has to push Relenza much more ! I hope that they ALREADY HAVE increased production massively, so that we wont have to wait until next year for the 190 million courses...
We will know more end of October.
Best regards from Germany
Eric
BTA Price at posting:
$2.73 Sentiment: Hold Disclosure: Held
